References
- Bae JW, Choi CI, Kim MJ, et al. (2011). Frequency of CYP2C9 alleles in Koreans and their effects on losartan pharmacokinetics. Acta Pharmacol Sin 32:1303–8
- Cabaleiro T, Roman M, Ochoa D, et al. (2013). Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers. Drug Metab Dispos 41:224–9
- Dahlof B, Devereux RB, Kjeldsen SE, et al. (2002). Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359:995–1003
- Dai DP, Xu RA, Hu LM, et al. (2013). CYP2C9 polymorphism analysis in Han Chinese populations: building the largest allele frequency database. Pharmacogenomics J. doi: 10.1038/tpj.2013.2 [Epub ahead of print 12 Feb 2013]
- DeLozier TC, Lee SC, Coulter SJ, et al. (2005). Functional characterization of novel allelic variants of CYP2C9 recently discovered in southeast Asians. J Pharmacol Exp Ther 315:1085–90
- Hiratsuka M. (2012). In vitro assessment of the allelic variants of cytochrome P450. Drug Metab Dispos 27:68–84
- Hirota T, Eguchi S, Ieiri I. (2013). Impact of genetic polymorphisms in CYP2C9 and CYP2C19 on the pharmacokinetics of clinically used drugs. Drug Metab Pharmacokinet 28:28–37
- Hong X, Zhang S, Mao G, et al. (2005). CYP2C9*3 allelic variant is associated with metabolism of irbesartan in Chinese population. Eur J Clin Pharmacol 61:627–34
- Jose R, Chandrasekaran A, Sam SS, et al. (2005). CYP2C9 and CYP2C19 genetic polymorphisms: frequencies in the south Indian population. Fund Clin Pharmacol 19:101–5
- Lee CR, Pieper JA, Frye RF, et al. (2003). Tolbutamide, flurbiprofen, and losartan as probes of CYP2C9 activity in humans. J Clin Pharmacol 43:84–91
- Maekawa K, Harakawa N, Sugiyama E, et al. (2009). Substrate-dependent functional alterations of seven CYP2C9 variants found in Japanese subjects. Drug Metab Dispos 37:1895–903
- Rathore SS, Agarwal SK, Pande S, et al. (2010). Frequencies of VKORC1-1639 G > A, CYP2C9*2 and CYP2C9*3 genetic variants in the Northern Indian population. Biosci Trends 4:333–7
- Schelleman H, Limdi NA, Kimmel SE. (2008). Ethnic differences in warfarin maintenance dose requirement and its relationship with genetics. Pharmacogenomics 9:1331–46
- Schwarz UI. (2003). Clinical relevance of genetic polymorphisms in the human CYP2C9 gene. Eur J Clin Invest 33:23–30
- Takanashi K, Tainaka H, Kobayashi K, et al. (2000). CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates. Pharmacogenetics 10:95–104
- Timmermans PB, Wong PC, Chiu AT, et al. (1993). Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 45:205–51
- Van Booven D, Marsh S, McLeod H, et al. (2010). Cytochrome P450 2C9-CYP2C9. Pharmacogenet Genom 20:277–81
- Xie HG, Prasad HC, Kim RB, Stein CM. (2002). CYP2C9 allelic variants: ethnic distribution and functional significance. Adv Drug Deliver Rev 54:1257–70
- Yasar U, Forslund-Bergengren C, Tybring G, et al. (2002). Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. Clin Pharmacol Ther 71:89–98
- Yasar U, Tybring G, Hidestrand M, et al. (2001). Role of CYP2C9 polymorphism in losartan oxidation. Drug Metab Dispos 29:1051–6
- Yin T, Maekawa K, Kamide K, et al. (2008). Genetic variations of CYP2C9 in 724 Japanese individuals and their impact on the antihypertensive effects of losartan. Hypertens Res 31:1549–57
- Zhou SF, Liu JP, Chowbay B. (2009a). Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev 41:89–295
- Zhou SF, Zhou ZW, Huang M. (2010). Polymorphisms of human cytochrome P450 2C9 and the functional relevance. Toxicology 278:165–88
- Zhou SF, Zhou ZW, Yang LP, Cai JP. (2009b). Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem 16:3480–675